Full-Time

Machine Learning Scientist

Confirmed live in the last 24 hours

BigHat Biosciences

BigHat Biosciences

51-200 employees

Develops antibody therapies using machine learning

AI & Machine Learning
Biotechnology

Senior, Expert

San Mateo, CA, USA

Category
Applied Machine Learning
Deep Learning
AI & Machine Learning
Required Skills
Python
Data Science
Pytorch
Machine Learning
Requirements
  • PhD in ML/CS or in the hard sciences with equivalent experience developing and applying novel ML methods and a strong quantitative background.
  • Publications in major ML conferences and/or leading journals, or extensive demonstrable track record developing and applying novel ML in industry.
  • Strong competency in Python, familiarity with PyTorch, and experience with modern software engineering best practices.
  • Excellent communication skills, sufficient biomedical domain knowledge to interact effectively with diverse scientific teams.
  • Enjoys a fast-paced environment and excels at executing across multiple projects.
Responsibilities
  • Design and implement the next state-of-the-art generative models of antibody sequence and structure, and predictive models of antibody properties, trained on proprietary internal datasets of thousands to millions of antibodies.
  • Develop multi-modality, multi-objective iterative protein sequence optimization approaches to lab-in-the-loop antibody design problems for validation and deployment in our high-throughput wet lab - at BigHat success is only declared upon synthesis of real antibodies with drug-like properties.
  • Share your findings at top-tier conferences and publish in leading scientific journals to advance the field of protein engineering.
  • Provide ML expertise and support for ongoing therapeutics programs, directly contributing to the development of new drugs.
  • Collaborate with our engineering team to ensure maximal efficiency in the automated deployment of our latest models to ongoing drug development programs.
  • Work closely with an interdisciplinary team of drug developers, wet lab scientists, automation specialists, data scientists, etc. to identify inefficiencies or potential improvements in the BigHat ML platform, and plan the next phase of ML research accordingly.
Desired Qualifications
  • Experience with protein structure modeling and biophysics.
  • Familiarity with NGS data.
  • Familiarity with antibody biology.
  • Experience training and deploying models on AWS.

BigHat Biosciences focuses on developing antibody therapies using machine learning and synthetic biology. Their main product is the Milliner platform, which integrates a wet lab with advanced machine learning to streamline the discovery and engineering of antibodies. This platform enables the rapid synthesis, purification, and characterization of numerous recombinant antibodies each week, allowing for quicker development of effective treatments for challenging diseases like certain infections and cancers. Unlike many competitors, BigHat emphasizes a balance between high performance and a supportive work culture. The company's goal is to create safer and more effective therapies for patients while maintaining a family-friendly work environment.

Company Stage

Series B

Total Funding

$96.6M

Headquarters

San Carlos, California

Founded

2019

Growth & Insights
Headcount

6 month growth

1%

1 year growth

0%

2 year growth

0%
Simplify Jobs

Simplify's Take

What believers are saying

  • AI-driven protein engineering is crucial for personalized medicine, benefiting BigHat's platform.
  • Recent ADC advancements open new cancer treatment avenues, aligning with BigHat's focus.
  • BigHat's collaborations with AI firms lead to innovative drug development solutions.

What critics are saying

  • Increased ADC competition may overshadow BigHat's collaborations, affecting market position.
  • Biotech market volatility poses risks to BigHat's expansion despite current growth.
  • Substantial funding needs highlight financial risks if future rounds fall short.

What makes BigHat Biosciences unique

  • BigHat's Milliner platform integrates AI with synthetic biology for rapid antibody development.
  • The company focuses on difficult-to-treat diseases, enhancing treatment options for complex conditions.
  • BigHat's strategic collaborations with industry leaders like Janssen and Merck boost its innovation.

Help us improve and share your feedback! Did you find this helpful?